Custom Antibody Market Report 2026

The custom antibody market size has grown rapidly in recent years. It will grow from $0.47 billion in 2025 to $0.53 billion in 2026 at a compound annual growth rate (CAGR) of 12.9%. The growth in the historic period can be attributed to growth in biomedical research, expansion of diagnostics testing, increased pharma r&d spending, advances in antibody engineering, growth of academic research.

The custom antibody market size is expected to see rapid growth in the next few years. It will grow to $0.86 billion in 2030 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to growth in personalized medicine, expansion of biologics research, increasing cro utilization, rising diagnostic demand, growth in precision oncology. Major trends in the forecast period include rising demand for tailored research antibodies, increasing use in precision diagnostics, growing adoption in drug discovery pipelines, expansion of recombinant antibody technologies, increased outsourcing to cros.

The increasing demand for personalized medicine is anticipated to drive the expansion of the custom antibody industry in the coming years. Personalized medicine is a medical approach that adapts treatment and prevention strategies based on an individual’s genetic profile, lifestyle, and environmental influences. The rising demand for personalized medicine is fueled by progress in genomics, greater availability of biomarker-driven therapies, and an increasing preference among patients for customized treatment options that enhance effectiveness and minimize side effects. Custom antibodies support personalized medicine by offering specific and tailored immune reagents that improve disease detection, therapeutic targeting, and biomarker identification for individualized treatment approaches. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the Food and Drug Administration (FDA) approved 16 new personalized therapies for rare disease patients, up from 6 in 2022. Consequently, the rising demand for personalized medicine is contributing to the growth of the custom antibody sector.

Major companies in the custom antibody sector are increasingly focusing on incorporating advanced technologies such as artificial intelligence to improve antibody discovery, enhance specificity, and speed up development processes. Artificial intelligence aids custom antibody development by optimizing antigen selection, predicting antibody-antigen interactions, and facilitating candidate screening through machine learning, resulting in faster and more cost-efficient biopharmaceutical research. For example, in October 2024, Archon Biosciences Inc., a US-based biotech firm, launched with $20 million in funding to create computationally designed antibody cages that allow the modification of existing antibodies for therapeutic use. Archon’s proprietary platform assembles antibodies into cage structures, enabling adjustments to their properties without changing their core structures. This innovation is designed to improve antibody affinity for therapeutic targets while minimizing off-target effects, enhancing both efficacy and safety.

In September 2024, Leinco Technologies Inc., a US-based biotechnology firm, acquired QED Biosciences Inc. for an undisclosed sum. Through this acquisition, Leinco Technologies aims to drive its strategic growth, broaden its market presence, and strengthen its offerings in the life science and IVD raw material sectors. QED Biosciences Inc. is a US-based biotechnology company focused on designing and producing custom antibodies.

Major companies operating in the custom antibody market are Merck & Co. Inc., AbbVie Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Lonza Group AG, Bio-Rad Laboratories Inc., Bio-Techne Corporation, GenScript Biotech Corporation, BioLegend Inc., Abcam plc, Cusabio Biotech Co. Ltd., OriGene Technologies Inc., Cell Signaling Technology Inc., Abgent Inc., ProSci Incorporated, Santa Cruz Biotechnology Inc., Rockland Immunochemicals Inc., Creative Biolabs Inc., Novus Biologicals LLC, Creative Diagnostics Inc., Biorbyt Ltd., BIOTEM SAS, Capra Biosciences Inc., Pacific Immunology Inc., ProteoGenix SAS.

North America was the largest region in the custom antibody market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the custom antibody market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the custom antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased the cost of reagents, laboratory equipment, and antibody production inputs used across research and diagnostic workflows. The impact is most pronounced in research and diagnostic applications, where access to specialized materials and instruments is critical. Regions such as North America and Europe have experienced higher input costs due to reliance on global life science supply chains. Rising tariff related expenses have influenced research budgets, testing costs, and procurement planning. Tariffs have encouraged localized antibody production, regional supplier development, and stronger domestic life science manufacturing ecosystems over the long term.

The custom antibody market research report is one of a series of new reports that provides custom antibody market statistics, including custom antibody industry global market size, regional shares, competitors with a custom antibody market share, detailed custom antibody market segments, market trends and opportunities, and any further data you may need to thrive in the custom antibody industry. This custom antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A custom antibody is an antibody produced in a laboratory that is specifically designed to recognize a particular antigen of interest. These antibodies are created to meet the specific requirements of researchers or healthcare professionals for research, diagnostic, or therapeutic purposes. They are extensively utilized in biomedical research, diagnostics, and drug development, allowing accurate detection and targeting of biomolecules.

The main categories of custom antibodies include monoclonal antibodies, polyclonal antibodies, recombinant antibodies, and other varieties. Monoclonal antibodies are laboratory-engineered molecules created to target a specific antigen, replicating the immune system’s natural ability to fight pathogens. The services offered in this field encompass antibody development, antibody production and purification, as well as antibody fragmentation and labeling. The sources of custom antibodies consist of mice, rabbits, and other origins. These antibodies find applications across various areas, such as oncology, infectious diseases, neurology, stem cell research, immunology, and cardiovascular disorders. The primary end users of custom antibodies include pharmaceutical and biotechnology companies, academic and research institutions, contract research organizations, and hospitals and clinics.

The custom antibody market consists of revenues earned by entities by providing services such as antibody production, antibody purification, and conjugation. The market value includes the value of related goods sold by the service provider or included within the service offering. The custom antibody market also consists of sales of products including antibody fragments, conjugated antibodies, and secondary antibodies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.